RNAZ News & Events

TransCode Therapeutics announced the initiation of its Phase 2a clinical trial. The study is to evaluate TransCode's lead therapeutic candidate, TTX-MC138, in patients with circulating tumor DNA positive colorectal cancer following curative-intent therapy. The trial is being conducted in collaboration with Quantum Leap Healthcare Collaborative, sponsor of the PRE-I-SPY clinical trial platform. The trial builds on growing clinical and scientific momentum supporting ctDNA-guided strategies targeting minimal residual disease in colorectal cancer. The Phase 2a clinical trial is expected to enroll up to 45 patients with colorectal cancer who have completed standard curative-intent therapy and have no radiographic evidence of disease, but remain or become ctDNA-positive, indicating the presence of minimal residual disease.

Transcode Therapeutics files to sell 15.96M shares of common stock for holders

TransCode Therapeutics appointed Anna Moore as Chair of its Scientific Advisory Board. Moore, Associate Dean for Research Development, Director of the Precision Health Program and Professor in the Departments of Radiology and Physiology at Michigan State University, is a co-founder of TransCode Therapeutics and expert in molecular imaging and RNA-targeted cancer therapeutics. Prior to joining MSU, she had a 26-year career at Massachusetts General Hospital and Harvard Medical School, where she served as Professor of Radiology and Director of the Molecular Imaging Laboratory.